Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis;Les antagonistes du récepteur minéralocorticoïde sont-ils sécuritaires chez les patients hémodialysés?

Annals of Pharmacotherapy

Volumn 46, Issue 6, 2012, Pages 889-894

  Baker, William L ^a   White, William B ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Eplerenone; Hemodialysis; Hypertension; Mineralocorticoid antagonists; Spironolactone

Indexed keywords

ALDOSTERONE; EPLERENONE; MINERALOCORTICOID ANTAGONIST; POTASSIUM; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; ARTICLE; DRUG SAFETY; HEMODIALYSIS; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ALDOSTERONE ANTAGONISTS; HUMANS; KIDNEY FAILURE, CHRONIC; POTASSIUM; RECEPTORS, MINERALOCORTICOID; RENAL DIALYSIS; SPIRONOLACTONE;

EID: 84862259587     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R011     Document Type: Article

References (28)

1. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-26. DOI 10.1161/HYPERTENSIONAHA.108.189141.
2. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
3. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
4. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21. DOI 10.1056/NEJMoq1009492.
5. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003;16: 925-30.
6. Ouzan J, Perault C, Lincoff AM, et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 2002; 15:333-9.
7. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008;2:462-8.
8. Jansen PM, Danser AHJ, Imholz BP, et al. Aldosterone-receptor antagonism in hypertension. J Hypertens 2009;27:680-91. DOI 10.1097/HJH.0b013e32832810ed
9. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001;110:438-41.
10. Ahmed J, Weisberg LS. Hyperkalemia in dialysis patients. Semin Dial 2001;14:348-56.
11. Product information. Inspra (eplerenone). New York, NY: Pfizer Inc, April 2008.
12. Product information. Aldactone (spironolactone). New York, NY: Pfizer Inc, January 2008.
13. Lindenfeld J, Albert NM, Boehmer JP, et al. Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010;16:475-539. DOI 10.1016/j.cardfail.2010.04.005.
14. Bomback AS, Kshirsagar AV, Ferris ME, et al. Disordered aldosteronevolume relationship in end-stage kidney disease. J Renin Angiotensin Aldosterone Syst 2009;10:230-6. DOI 10.1177/1470320309352353.
15. Brewster UC, Setaro JF, Perazella MA. The renin-angiotensin-aldosterone system: cardiorenal effects and implication for renal and cardiovascular disease states. Am J Med Sci 2003;326:15-24.
16. Ritz E, Tomaschitz A. Aldosterone, a vasculotoxic agent - novel functions for an old hormone. Nephrol Dial Transplant 2009;24:2302-5. DOI 10.1093/ndt/gfp206.
17. Saudan P, Mach F, Perneger T, et al. Safety of low-dose spironolactone administration in chronic haemodialysis patients. Nephrol Dial Transplant 2003;18:2359-63.
18. Taheri S, Mortazavi M, Shahidi S, et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transpl 2009;20:392-7.
19. Papadimitriou M, Vyzantiadis A, Milionis A, et al. The effect of spironolactone in hypertensive patients on regular haemodialysis and after renal allotransplantation. Life Sup Syst 1983;1:197-205.
20. Sugarman A, Brown RS. The role of aldosterone in potassium tolerance: Studies in anephric humans. Kidney Int 1988;34:397-403.
21. Hussain S, Dreyfus DE, Marcus RJ, et al. Is spironolactone safe for dialysis patients? Nephrol Dial Transplant 2003;18:2364-8.
22. Michea L, Vukusich A, Gonzalez M, et al. Effect of spironolactone on K+ homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients. Kidney Int 2004;66:1647-53.
23. Gross E, Rothstein M, Dombek S, et al. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligoanuric hemodialysis patients. Am J Kidney Dis 2005;46:94-101. DOI 10.1053/j.ajkd.2005.03.005.
24. Matsumoto Y, Kageyama S, Yakushigawa T, et al. Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients. Cardiology 2009;114:32-8. DOI 10.1159/000210553.
25. Vukusich A, Kunstmann S, Varela C, et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol 2010;5:1380-7. DOI 10.2215/CJN.09421209.
26. Shavit L, Neykin D, Lifschitz M, Slotki I. Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - a pilot study. Clin Nephrol 2011;5:388-95. DOI 10.5414/CN106973.
27. Hausmann MJ, Liel-Cohen N. Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function. Nephrol Dial Transplant 2002;17:2035-6.
28. Azar R, Hogede L, Carru V. Aldactone in a peritoneal dialysis patient. Nephrol Dial Transplant 2003;18:1232.